A long-term follow-up approach for Parkinson's disease patients undergoing repetitive transcranial stimulation therapy

Abstract

The present invention relates to the field of transcranial stimulation therapy follow-up, and specifically to a long-term follow-up method for repeated transcranial stimulation therapy for Parkinson's patients. The method first obtains the physical sign data of each follow-up examination of Parkinson's patients before and after each repeated transcranial stimulation therapy. By analyzing the physical sign data of the patients in the follow-up before and after each treatment, a preliminary assessment of the deterioration trend of the disease is made. Considering that patients with irreversible brain damage may experience a temporary improvement after treatment, but then the condition worsens, resulting in a rebound of the physical sign data, the rebound physical sign data is screened out, and combined with the irreversible brain damage index, the possibility of irreversible brain damage in the patient before and after treatment is assessed. Finally, the irreversible brain damage assessment value accurately reflects the patient's brain damage degree, and the irreversible brain damage assessment values of all treatments are uploaded to a database, providing data support for analyzing the changing trend of irreversible brain damage in patients during long-term treatment, thereby improving the long-term follow-up effect.

Description

Technical Field

[0001] The present invention relates to the field of transcranial stimulation therapy follow-up, and in particular to a long-term follow-up method for repeated transcranial stimulation therapy for Parkinson's disease patients. Background Art

[0002] Parkinson's disease is caused by abnormal neuronal activity in the basal ganglia and cortical areas of the brain. There is currently no complete cure. Long-term treatment is usually performed using repetitive transcranial stimulation (rTMS) to alleviate the condition. However, during long-term treatment, Parkinson's symptoms may damage the patient's brain nerves and cause irreversible brain damage to the patient. Therefore, long-term follow-up examinations are required during the treatment process to assess the extent of irreversible brain damage in the patient in order to better analyze the patient's disease progression and improve the treatment plan for the patient.

[0003] In related technologies, the differences in Parkinson's disease-related physical sign data, such as the severity of white matter hyperintensities in patients, before and after treatment are usually analyzed to assess the extent of irreversible brain damage in patients. However, the irreversible brain damage caused by Parkinson's disease will have a certain impact on the changes in the patient's physical sign data. As a result, existing methods are unable to accurately assess the extent of the patient's irreversible brain damage based solely on the differences in physical sign data before and after treatment, thereby reducing the effectiveness of long-term follow-up of Parkinson's patients. Summary of the Invention

[0004] In order to solve the technical problem that existing methods cannot accurately assess the degree of irreversible brain damage in patients based solely on the differences in physical sign data before and after treatment, thereby reducing the effectiveness of long-term follow-up of Parkinson's patients, the purpose of the present invention is to provide a long-term follow-up method for repetitive transcranial stimulation treatment of Parkinson's patients. The technical solution adopted is as follows:

[0005] The present invention proposes a long-term follow-up method for repetitive transcranial stimulation therapy for Parkinson's disease patients, the method comprising:

[0006] Obtain the physical sign data of Parkinson's patients at each follow-up examination before and after each repetitive transcranial stimulation treatment;

[0007] Taking any treatment as the target treatment, the follow-up process before the target treatment as the preceding follow-up process, and the follow-up process after the target treatment as the subsequent follow-up process, and obtaining the trend value of the worsening condition of the Parkinson's disease patient during the target treatment based on the difference in the physical sign data of each follow-up examination between the preceding follow-up process and the subsequent follow-up process;

[0008] any one of the preceding follow-up process or the subsequent follow-up process is used as a target follow-up process, and based on the changes in the physical sign data of each follow-up examination in the target follow-up process, a plurality of rebound sign data are screened from the physical sign data of all follow-up examinations in the target follow-up process; based on the changes in each rebound sign data in the target follow-up process and the number of all rebound sign data, an irreversible brain damage index of the Parkinson's patient in the target follow-up process is obtained; based on the irreversible brain damage index of the Parkinson's patient in the preceding follow-up process and the subsequent follow-up process, and the disease worsening trend value of the Parkinson's patient in the target treatment, a possibility of irreversible brain damage in the Parkinson's patient during the target treatment is obtained;

[0009] Based on the possibility of irreversible brain damage in Parkinson's patients during the target treatment and the difference in the distribution of the physical sign data of each follow-up examination between the previous follow-up process and the subsequent follow-up process, the irreversible brain damage assessment value of Parkinson's patients during the target treatment is obtained, and the irreversible brain damage assessment value of Parkinson's patients in all treatments is uploaded to the database.

[0010] Furthermore, obtaining the disease progression trend value of the Parkinson's disease patient during target treatment includes:

[0011] Normalizing the difference between the physical sign data of the last follow-up examination in the preceding follow-up process and the physical sign data of the first follow-up examination in the subsequent follow-up process to obtain the temporary impact of the target treatment;

[0012] Obtaining the degree of sustained effect of the target treatment based on the difference in the overall level of the physical sign data of all follow-up examinations between the previous follow-up process and the subsequent follow-up process;

[0013] The difference between the temporary impact level and the persistent impact level is used as the disease progression trend value of the Parkinson's disease patient under target treatment.

[0014] Furthermore, the degree of sustained impact of achieving the target treatment includes:

[0015] The average value of the physical sign data of all follow-up examinations in the previous follow-up process is used as the first overall physical sign data of the previous follow-up process;

[0016] The average value of the physical sign data of all follow-up examinations in the subsequent follow-up process is used as the second overall physical sign data of the subsequent follow-up process;

[0017] The difference between the first overall vital sign data and the second overall vital sign data is normalized to obtain the degree of sustained impact of the target treatment.

[0018] Furthermore, the step of screening out a plurality of rebound vital sign data from the vital sign data of all follow-up examinations during the target follow-up process includes:

[0019] Mapping the vital sign data of all follow-up examinations during the target follow-up process into a two-dimensional coordinate system to obtain a plurality of data points, wherein the horizontal axis of the two-dimensional coordinate system represents the sequence number of the follow-up examination and the vertical axis represents the vital sign data;

[0020] Performing a curve fitting on all the data points to obtain a fitting curve, and using the follow-up examination corresponding to the minimum value data point on the fitting curve as a candidate follow-up examination in the target follow-up process;

[0021] Obtaining a trend deviation of the physical sign data of each to-be-selected follow-up examination based on the physical sign data of each to-be-selected follow-up examination, the physical sign data of the first follow-up examination in the target follow-up process, the physical sign data of the last follow-up examination in the target follow-up process, the sequence number of each to-be-selected follow-up examination, and the number of all follow-up examinations in the target follow-up process;

[0022] The average of the trend deviations of the physical sign data of all selected follow-up examinations is taken as the overall trend deviation;

[0023] The physical sign data of the selected follow-up examination whose trend deviation is greater than the overall trend deviation is used as rebound physical sign data.

[0024] Furthermore, obtaining the trend deviation of the physical sign data of each selected follow-up examination includes:

[0025] The difference between the physical sign data of each candidate follow-up examination and the physical sign data of the first follow-up examination in the target follow-up process is used as the numerator, the difference between the physical sign data of the last follow-up examination in the target follow-up process and the physical sign data of the first follow-up examination in the target follow-up process is used as the denominator, and the ratio is used as the first proportional coefficient of each candidate follow-up examination;

[0026] The serial number of each candidate follow-up examination is used as the numerator, the number of all follow-up examinations in the target follow-up process is used as the denominator, and the ratio is used as the second proportional coefficient of each candidate follow-up examination;

[0027] Based on the calculation formula of trend deviation, the trend deviation of the physical sign data of each selected follow-up examination is obtained. The calculation formula of trend deviation is:

[0028]

[0029] in, Indicates the first The trend deviation of the physical sign data of the selected follow-up examinations; Indicates the The first proportionality coefficient of the selected follow-up examinations; Indicates the The second proportionality factor for the selected follow-up examinations.

[0030] Furthermore, the irreversible brain damage indicators obtained in Parkinson's patients during the target follow-up process include:

[0031] The cumulative value of the trend deviation of all the rebound sign data in the target follow-up process is used as the comprehensive trend deviation of the target follow-up process;

[0032] The product value of the number of all the rebound sign data and the comprehensive trend deviation during the target follow-up process is used as an indicator of irreversible brain damage in Parkinson's patients during the target follow-up process.

[0033] Furthermore, the possibility of obtaining irreversible brain damage in Parkinson's patients under target treatment includes:

[0034] The average value of the irreversible brain damage index of the Parkinson's patient during the preceding follow-up process and the subsequent follow-up process is used as the irreversible brain damage coefficient of the Parkinson's patient in the target treatment;

[0035] The product value of the irreversible brain damage coefficient of the Parkinson's patient under target treatment and the disease worsening trend value is normalized to obtain the possibility of irreversible brain damage of the Parkinson's patient under target treatment.

[0036] Furthermore, obtaining an assessment value of irreversible brain damage in Parkinson's patients undergoing targeted treatment includes:

[0037] In the preceding follow-up process, the number of all follow-up examinations after the follow-up examination corresponding to the maximum value of all the vital sign data is used as a first number of the preceding follow-up process; in the subsequent follow-up process, the number of all follow-up examinations before the follow-up examination corresponding to the maximum value of all the vital sign data is used as a second number of the subsequent follow-up process; and a sum of the first number and the second number is negatively correlated and mapped to obtain a first assessment value of the Parkinson's patient at the target treatment;

[0038] Obtaining a second assessment value of the Parkinson's disease patient at target treatment based on a difference between a minimum value of all the physical sign data during a previous follow-up and a minimum value of all the physical sign data during a subsequent follow-up;

[0039] Combining the first assessment value and the second assessment value of the Parkinson's patient under target treatment and the possibility of irreversible brain damage to obtain a comprehensive assessment value of the Parkinson's patient under target treatment;

[0040] The comprehensive assessment values of Parkinson's patients under target treatment were normalized to obtain the assessment values of irreversible brain damage of Parkinson's patients under target treatment.

[0041] Furthermore, obtaining a second evaluation value of the Parkinson's disease patient under target treatment includes:

[0042] The minimum value of all the physical sign data in the subsequent follow-up process is used as the numerator, the minimum value of all the physical sign data in the previous follow-up process is used as the denominator, and the ratio is used as the second evaluation value of Parkinson's patients in target treatment.

[0043] Furthermore, obtaining a comprehensive evaluation value of Parkinson's disease patients in target treatment includes:

[0044] The product of the first assessment value, the second assessment value and the possibility of irreversible brain damage of the Parkinson's patient in the target treatment is used as the comprehensive assessment value of the Parkinson's patient in the target treatment.

[0045] The present invention has the following beneficial effects:

[0046] The present invention takes into account that the existing methods cannot accurately assess the degree of irreversible brain damage of patients based solely on the differences in physical sign data before and after treatment, thereby reducing the effectiveness of long-term follow-up of Parkinson's patients. Therefore, the physical sign data of the patients at each follow-up examination before and after each treatment are first obtained, and the differences in physical sign data between the previous follow-up process and the subsequent follow-up process are preliminarily analyzed. The degree to which the patient's condition has deteriorated after the target treatment is preliminarily reflected by the condition deterioration trend value. Considering that patients with irreversible brain damage have a temporary improvement in their condition after treatment and their physical sign data are reduced, their condition will deteriorate afterwards, resulting in an upward rebound phenomenon in the physical sign data. In other words, when patients have irreversible brain damage, it will affect the changing trend of the physical sign data. , and the impact produced in different follow-up processes is different. Therefore, the rebound sign data can be first screened out from the target follow-up process, and the obtained irreversible brain damage index can preliminarily reflect the possibility of irreversible brain damage in the patient during the target follow-up process, and the obtained irreversible brain damage possibility can further reflect the possibility of irreversible brain damage in the patient before and after the target treatment. Then, the irreversible brain damage assessment value can be used to accurately assess the degree of irreversible brain damage in the patient before and after the target treatment, and the irreversible brain damage assessment values of Parkinson's patients in all treatments can be uploaded to the database, which is convenient for relevant personnel to analyze the changing trend of irreversible brain damage in patients during long-term treatment to improve the data basis, thereby improving the effect of long-term follow-up of Parkinson's patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] In order to more clearly illustrate the technical solutions and advantages of the embodiments of the present invention or the prior art, the following briefly introduces the drawings required for use in the embodiments or the prior art descriptions. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0048] Figure 1 A flow chart of a long-term follow-up method for repetitive transcranial stimulation therapy for Parkinson's disease patients provided by one embodiment of the present invention;

[0049] Figure 2 This is a schematic diagram of the distribution of multiple repetitive transcranial stimulation treatments and follow-up examinations on the time axis provided by one embodiment of the present invention. DETAILED DESCRIPTION

[0050] To further illustrate the technical means and efficacy of the present invention to achieve the intended purpose, the following, in conjunction with the accompanying drawings and preferred embodiments, describes in detail a method for long-term follow-up of repetitive transcranial stimulation therapy for Parkinson's disease patients according to the present invention, including its specific implementation, structure, features, and efficacy. In the following description, different references to "one embodiment" or "another embodiment" do not necessarily refer to the same embodiment. Furthermore, specific features, structures, or characteristics of one or more embodiments may be combined in any suitable manner.

[0051] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0052] The specific scheme of the long-term follow-up method for repeated transcranial stimulation treatment of Parkinson's disease patients provided by the present invention is described in detail below with reference to the accompanying drawings.

[0053] See also Figure 1 , which shows a flow chart of a long-term follow-up method for repetitive transcranial stimulation treatment of Parkinson's disease patients provided by one embodiment of the present invention, the method comprising:

[0054] Step S1: Obtaining the physical sign data of Parkinson's patients during each follow-up examination before and after each repetitive transcranial stimulation treatment.

[0055] Repetitive transcranial stimulation is an effective treatment for Parkinson's disease, and long-term treatment is required for Parkinson's patients. Therefore, an embodiment of the present invention first obtains physical sign data from each follow-up examination of Parkinson's patients before and after each repetitive transcranial stimulation treatment. The physical sign data is data related to Parkinson's disease and can reflect the degree of damage to the brain nerves of Parkinson's patients to a certain extent. For example, data such as the severity of white matter hyperintensities or the levels of certain proteins in the cerebrospinal fluid can be used as physical sign data. In one embodiment of the present invention, the severity of white matter hyperintensities is used as physical sign data. The process for obtaining the severity of white matter hyperintensities is as follows: first, in each follow-up examination, a magnetic resonance imaging device is used to collect white matter hyperintensities of Parkinson's patients, and then the severity of white matter hyperintensities of Parkinson's patients in each follow-up examination is evaluated and quantified using existing methods such as the Fazekas visual rating scale or the Scheltens scale, and the quantified results are used as physical sign data for each follow-up examination.

[0056] It should be noted that, in one embodiment of the present invention, the time period between a certain repetitive transcranial stimulation treatment and the previous treatment is used as the follow-up process before the repetitive transcranial stimulation treatment, and the time period between a certain repetitive transcranial stimulation treatment and the next treatment is used as the follow-up process after the repetitive transcranial stimulation treatment, and multiple follow-up examinations are required for the patient before the first treatment and after the last treatment. Figure 2 , which shows a schematic distribution diagram of multiple repeated transcranial stimulation treatments and follow-up examinations on the time axis provided by an embodiment of the present invention, wherein Q1, Q2, Q3 and Q4 respectively represent the first, second, third and fourth repeated transcranial stimulation treatments of Parkinson's patients. The patient underwent four follow-up examinations in the follow-up process before the first repeated transcranial stimulation treatment Q1, and underwent three follow-up examinations in the follow-up process after the first repeated transcranial stimulation treatment Q1, which were P1, P2 and P3 respectively.

[0057] It should be noted that the frequency of repetitive transcranial stimulation treatment and the frequency of follow-up examinations need to be dynamically adjusted by relevant medical staff according to the actual condition of Parkinson's patients throughout the process. That is to say, the time interval between two adjacent treatments and the time interval between two adjacent follow-up examinations may be different.

[0058] Step S2: Take any treatment as the target treatment, the follow-up process before the target treatment as the preceding follow-up process, and the follow-up process after the target treatment as the subsequent follow-up process. According to the difference in the physical sign data of each follow-up examination between the preceding follow-up process and the subsequent follow-up process, the trend value of the deterioration of the Parkinson's disease in the target treatment is obtained.

[0059] Since there are differences in the physical sign data before and after different repetitive transcranial stimulation treatments, the possibility and degree of irreversible brain damage in Parkinson's patients before and after different repetitive transcranial stimulation treatments are different. Therefore, it is necessary to analyze any repetitive transcranial stimulation treatment, take any treatment as the target treatment, and take the follow-up process before the target treatment as the pre-sequence follow-up process, and take the follow-up process after the target treatment as the subsequent follow-up process. The physical sign data of each follow-up examination in the pre-sequence follow-up process can be expressed as ,in, Indicates the first The physical sign data of the follow-up examination, represents the number of follow-up examinations during the preceding follow-up period. The physical sign data of each follow-up examination during the subsequent follow-up period can be expressed as ,in, Indicates the first The physical sign data of the follow-up examination, Indicates the number of follow-up examinations during subsequent follow-up.

[0060] Repetitive transcranial stimulation therapy achieves the purpose of relieving Parkinson's disease by stimulating the patient's brain nerves, so that the patient's higher vital sign data can be reduced to a certain extent. If the patient has irreversible brain damage, the vital sign data will decrease briefly and then show an upward deterioration trend again. Therefore, the difference in vital sign data of each follow-up examination between the previous follow-up process and the subsequent follow-up process can be analyzed. The obtained disease deterioration trend value can preliminarily reflect the degree of deterioration of the patient's condition after the target treatment, providing a data basis for subsequent analysis of the possibility of irreversible brain damage in Parkinson's patients before and after the target treatment.

[0061] Preferably, in one embodiment of the present invention, the method for obtaining the disease progression trend value of a Parkinson's disease patient during target treatment specifically includes:

[0062] First, the difference between the physical sign data of the last follow-up examination in the previous follow-up process and the physical sign data of the first follow-up examination in the subsequent follow-up process was normalized to obtain the temporary impact of the target treatment. The greater the temporary impact, the more it means that after the target treatment, the Parkinson's disease patient's condition has been temporarily relieved and the patient's physical sign data has been temporarily reduced.

[0063] Considering that when patients have irreversible brain damage, repeated transcranial stimulation therapy has limited effect on alleviating the disease, and the patient's vital signs data will rise again or even deteriorate further after a period of time, it is impossible to accurately reflect whether the patient has irreversible brain damage through the temporary impact degree. Therefore, it is necessary to obtain the sustained impact degree of the target treatment based on the difference in the overall level of the vital signs data of all follow-up examinations between the previous follow-up process and the subsequent follow-up process. The sustained impact degree reflects the degree to which the condition of Parkinson's patients is sustained after the target treatment. Subsequently, the temporary impact degree and the sustained impact degree can be combined to calculate and analyze the trend value of the deterioration of the condition of Parkinson's patients during the target treatment.

[0064] Preferably, in one embodiment of the present invention, the method for obtaining the disease progression trend value of a Parkinson's disease patient during target treatment specifically includes:

[0065] The average value of the physical sign data of all follow-up examinations in the previous follow-up process is used as the first overall physical sign data of the previous follow-up process; the average value of the physical sign data of all follow-up examinations in the subsequent follow-up process is used as the second overall physical sign data of the subsequent follow-up process; the difference between the first overall physical sign data and the second overall physical sign data is normalized to obtain the degree of sustained impact of the target treatment.

[0066] The greater the degree of temporary impact compared to the degree of persistent impact, the more it means that the patient's vital sign data shows an upward deterioration trend again after a brief decrease, which further indicates that the patient is more likely to have irreversible brain damage before and after the target treatment. Therefore, the difference between the degree of temporary impact and the degree of persistent impact can be used as the deterioration trend value of Parkinson's disease patients during target treatment.

[0067] As an example, in one embodiment of the present invention, the expression for the worsening trend value of the Parkinson's disease in a patient undergoing target treatment may be specifically, for example, as follows:

[0068]

[0069]

[0070]

[0071] in, Indicates the trend value of Parkinson's disease worsening in patients with target treatment; Indicates the degree of temporary effect of the target treatment; Indicates the degree of sustained impact of the target treatment; It indicates the physical sign data of the last follow-up examination during the previous follow-up process; It represents the physical sign data of the first follow-up examination during the subsequent follow-up process; Indicates the first overall physical sign data of the preceding follow-up process; Represents the second overall physical sign data of the subsequent follow-up process; Represents an activation function, which is used for normalization processing. In other embodiments of the present invention, other normalization methods may also be used to implement normalization processing, which is not limited here.

[0072] Step S3: taking any one of the preceding follow-up processes or the subsequent follow-up processes as the target follow-up process, and screening out a plurality of rebound sign data from the sign data of all follow-up examinations in the target follow-up process based on the changes in the sign data of each follow-up examination in the target follow-up process; obtaining an irreversible brain damage index of the Parkinson's disease patient in the target follow-up process based on the changes in each rebound sign data and the number of all rebound sign data in the target follow-up process; and obtaining the possibility of irreversible brain damage of the Parkinson's disease patient in the target treatment based on the irreversible brain damage index of the Parkinson's disease patient in the preceding follow-up process and the subsequent follow-up process, as well as the disease worsening trend value of the Parkinson's disease patient in the target treatment.

[0073] For patients with irreversible brain damage, although the condition improves temporarily after treatment and the vital sign data decreases, the condition will worsen afterwards, resulting in an upward rebound phenomenon in the vital sign data. That is to say, when patients suffer from irreversible brain damage, it will affect the changing trend of the vital sign data, and the impact will be different in different follow-up processes. Therefore, first, any follow-up process in the previous follow-up process or the subsequent follow-up process is used as the target follow-up process, and then the changes in the vital sign data of each follow-up examination in the target follow-up process are analyzed, and multiple rebound sign data are screened out from the vital sign data of all follow-up examinations in the target follow-up process. Subsequently, based on the changes and quantity of each rebound sign data in the target follow-up process, the possibility of Parkinson's patients suffering from irreversible brain damage in the target follow-up process can be analyzed.

[0074] Preferably, in one embodiment of the present invention, the method for acquiring multiple rebound sign data during target follow-up specifically includes:

[0075] First, the vital sign data of all follow-up examinations during the target follow-up process are mapped into a two-dimensional coordinate system to obtain multiple data points, where the horizontal axis of the two-dimensional coordinate system represents the serial number of the follow-up examination and the vertical axis represents the vital sign data.

[0076] A curve is fitted for all data points to obtain a fitting curve, and the follow-up examination corresponding to the minimum data point on the fitting curve is used as a candidate follow-up examination in the target follow-up process. The more likely the vital sign data of the candidate follow-up examination is to be rebound vital sign data, the less likely the least squares method or other methods may be used for curve fitting in the embodiment of the present invention, which is not limited here.

[0077] Then, if a certain vital sign data shows an upward rebound phenomenon, and the degree of upward rebound is large, the change trend of the vital sign data deviates more from the overall trend of all vital sign data changes. Therefore, the trend deviation of the vital sign data of each to-be-selected follow-up examination can be obtained according to the vital sign data of each to-be-selected follow-up examination, the vital sign data of the first follow-up examination in the target follow-up process, the vital sign data of the last follow-up examination in the target follow-up process, the sequence number of each to-be-selected follow-up examination, and the number of all follow-up examinations in the target follow-up process. The greater the trend deviation of a certain vital sign data, the more the change trend of the vital sign data deviates from the overall change trend of the vital sign data, and the more likely the vital sign data is to show an upward rebound phenomenon and is to be rebound vital sign data.

[0078] Preferably, in one embodiment of the present invention, the method for obtaining the trend deviation of each physical sign data of the selected follow-up examination specifically includes:

[0079] The difference between the physical sign data of each candidate follow-up examination and the physical sign data of the first follow-up examination in the target follow-up process is used as the numerator, the difference between the physical sign data of the last follow-up examination in the target follow-up process and the physical sign data of the first follow-up examination in the target follow-up process is used as the denominator, and the ratio is used as the first proportional coefficient of each candidate follow-up examination.

[0080] The serial number of each candidate follow-up examination is used as the numerator, the number of all follow-up examinations in the target follow-up process is used as the denominator, and the ratio is used as the second proportional coefficient of each candidate follow-up examination, wherein the number of all follow-up examinations in the target follow-up process can also be understood as the serial number of the last follow-up examination in the target follow-up process.

[0081] The further the ratio of the first proportional coefficient to the second proportional coefficient of a candidate follow-up examination is from the value 1, the more the change trend of the physical sign data of the candidate follow-up examination deviates from the overall change trend of the physical sign data. Therefore, based on the calculation formula of the trend deviation, the trend deviation of the physical sign data of each candidate follow-up examination can be obtained. The calculation formula of the trend deviation is:

[0082]

[0083]

[0084]

[0085] in, Indicates the first The trend deviation of the physical sign data of the selected follow-up examinations; Indicates the The first proportionality coefficient of the selected follow-up examinations; Indicates the The second proportionality factor for the number of follow-up examinations to be selected; Indicates the first Physical sign data of the selected follow-up examinations; It represents the physical sign data of the first follow-up examination during the target follow-up; It indicates the physical sign data of the last follow-up examination during the target follow-up; Indicates the first The serial number of the selected follow-up examination; It indicates the number of all follow-up examinations in the target follow-up process, and can also be understood as the serial number of the last follow-up examination in the target follow-up process.

[0086] Secondly, considering that during the target follow-up process, other reasons besides irreversible brain damage may also cause the physical sign data to rebound, but the degree of the rebound caused by other reasons is smaller than that caused by irreversible brain damage, the smaller the degree to which the change trend of the physical sign data caused by other reasons deviates from the overall change trend of the physical sign data, the average value of the trend deviation of the physical sign data of all the selected follow-up examinations can be used as the overall trend deviation, and the physical sign data of the selected follow-up examinations with a trend deviation greater than the overall trend deviation can be used as rebound physical sign data, so that the multiple rebound physical sign data screened out are caused by irreversible brain damage.

[0087] The greater the deviation of the change trend of each rebound sign data during the target follow-up process from the overall change trend of the sign data, and the greater the number of rebound sign data, the greater the possibility of irreversible brain damage during the target follow-up process. Therefore, based on the change of each rebound sign data during the target follow-up process and the number of all rebound sign data, the irreversible brain damage index of Parkinson's patients during the target follow-up process can be obtained. The larger the irreversible brain damage index, the greater the possibility of irreversible brain damage during the target follow-up process.

[0088] Preferably, in one embodiment of the present invention, the method for obtaining irreversible brain damage indicators of Parkinson's patients during the target follow-up process specifically includes:

[0089] The cumulative value of the trend deviation of all rebound sign data during the target follow-up process is used as the comprehensive trend deviation of the target follow-up process. The larger the comprehensive trend deviation, the greater the deviation of the change trend of each rebound sign data during the target follow-up process relative to the overall change trend of the sign data. Therefore, the product value of the number of all rebound sign data during the target follow-up process and the comprehensive trend deviation can be used as an indicator of irreversible brain damage in Parkinson's patients during the target follow-up process.

[0090] As an example, in one embodiment of the present invention, the expression of the irreversible brain damage indicator of Parkinson's patients during the target follow-up process can be specifically, for example:

[0091]

[0092] in, Indicates the irreversible brain damage index of Parkinson's patients during the target follow-up process; Indicates the number of all rebound sign data during the target follow-up; Indicates the first The trend deviation of rebound sign data; Indicates the comprehensive trend deviation of the target follow-up process.

[0093] The same method as above can be used to obtain the irreversible brain damage index of Parkinson's patients in the previous follow-up process and the irreversible brain damage index in the subsequent follow-up process. The larger the irreversible brain damage index of Parkinson's patients in the previous follow-up process and the subsequent follow-up process, and the larger the trend value of Parkinson's patients' disease worsening during target treatment, the greater the possibility of Parkinson's patients suffering from irreversible brain damage in the follow-up period before and after target treatment. Therefore, based on the irreversible brain damage index of Parkinson's patients in the previous follow-up process and the subsequent follow-up process, and the trend value of Parkinson's patients' disease worsening during target treatment, the possibility of irreversible brain damage in Parkinson's patients during target treatment can be obtained. Subsequently, based on the possibility of irreversible brain damage, the degree of irreversible brain damage in Parkinson's patients during the follow-up period before and after target treatment can be accurately assessed.

[0094] Preferably, in one embodiment of the present invention, the method for obtaining the possibility of irreversible brain damage in a Parkinson's patient during target treatment specifically includes:

[0095] The average value of the irreversible brain damage index of Parkinson's patients in the previous follow-up process and the subsequent follow-up process is used as the irreversible brain damage coefficient of Parkinson's patients in target treatment. The larger the irreversible brain damage coefficient, the greater the possibility of Parkinson's patients suffering from irreversible brain damage in the follow-up period before and after target treatment. The product value of the irreversible brain damage coefficient of Parkinson's patients in target treatment and the disease deterioration trend value is normalized to obtain the possibility of irreversible brain damage of Parkinson's patients in target treatment.

[0096] As an example, in one embodiment of the present invention, the expression for the probability of irreversible brain damage in Parkinson's patients during target treatment can be specifically, for example:

[0097]

[0098] in, Indicates the likelihood of irreversible brain damage in Parkinson's patients at the target of treatment; It represents the irreversible brain damage index of Parkinson's patients during the previous follow-up process; It indicates the irreversible brain damage index of Parkinson's patients during the subsequent follow-up process; It represents the irreversible brain damage coefficient of Parkinson's patients at the target treatment; Indicates the trend value of Parkinson's disease worsening in patients with target treatment; Represents the activation function, which is used for normalization.

[0099] Step S4: Based on the possibility of irreversible brain damage in Parkinson's patients during the target treatment and the difference in the distribution of physical sign data of each follow-up examination between the previous follow-up process and the subsequent follow-up process, the irreversible brain damage assessment value of Parkinson's patients during the target treatment is obtained, and the irreversible brain damage assessment values of Parkinson's patients during all treatments are uploaded to the database.

[0100] After obtaining the possibility of irreversible brain damage in Parkinson's patients during target treatment, it is necessary to evaluate the degree of irreversible brain damage in Parkinson's patients before and after the target treatment. When the possibility of irreversible brain damage in Parkinson's patients is greater, the greater the difference in the distribution of physical sign data of each follow-up examination between the previous follow-up process and the subsequent follow-up process, the more severe the degree of irreversible brain damage in Parkinson's patients before and after the target treatment. Therefore, based on the possibility of irreversible brain damage in Parkinson's patients during target treatment and the difference in the distribution of physical sign data of each follow-up examination between the previous follow-up process and the subsequent follow-up process, the irreversible brain damage assessment value of Parkinson's patients during target treatment can be obtained, and the irreversible brain damage assessment value can accurately reflect the severity of irreversible brain damage in Parkinson's patients during the follow-up period before and after the target treatment.

[0101] Preferably, in one embodiment of the present invention, the method for obtaining the irreversible brain damage assessment value of a Parkinson's disease patient during target treatment specifically includes:

[0102] In the preceding follow-up process, the number of all follow-up examinations after the follow-up examination corresponding to the maximum value of all vital sign data is taken as the first number of the preceding follow-up process; in the subsequent follow-up process, the number of all follow-up examinations before the follow-up examination corresponding to the maximum value of all vital sign data is taken as the second number of the subsequent follow-up process. The smaller the first number and the second number are, the fewer follow-up examinations the Parkinson's patient's vital sign data has undergone from the most severe period before the target treatment to the most severe period again after the target treatment, which further indicates that the irreversible brain damage of the Parkinson's patient during the target treatment is more severe. The sum of the first number and the second number can be negatively correlated to obtain the first evaluation value of the Parkinson's patient during the target treatment.

[0103] As an example, in one embodiment of the present invention, the expression of the first evaluation value of a Parkinson's patient under target treatment may be specifically, for example, as follows:

[0104]

[0105] in, It represents the first assessment value of Parkinson's patients at the target treatment; represents the first number of the preceding follow-up process; The second number representing the subsequent follow-up process; Expressed as a natural constant An exponential function with base , used for negative correlation mapping.

[0106] It should be noted that in other embodiments of the present invention, negative correlation mapping may be achieved through other basic mathematical operations, which will not be described in detail here.

[0107] The smaller the minimum value of all physical sign data during the previous follow-up is relative to the minimum value of all physical sign data during the subsequent follow-up, the stronger the inhibition of Parkinson's disease patients' irreversible brain damage on the effect of repetitive transcranial stimulation treatment, which further indicates that the irreversible brain damage in Parkinson's disease patients during the follow-up period before and after the target treatment is more severe. Therefore, the second assessment value of Parkinson's disease patients in the target treatment can be obtained based on the difference between the minimum value of all physical sign data during the previous follow-up and the minimum value of all physical sign data during the subsequent follow-up.

[0108] Preferably, in one embodiment of the present invention, the method for obtaining the second evaluation value of a Parkinson's patient during target treatment specifically includes:

[0109] The minimum value of all physical sign data during the subsequent follow-up process is used as the numerator, the minimum value of all physical sign data during the previous follow-up process is used as the denominator, and the ratio is used as the second assessment value of Parkinson's patients in target treatment.

[0110] As an example, in one embodiment of the present invention, the expression of the second evaluation value of the Parkinson's disease patient under target treatment can be specifically, for example, as follows:

[0111]

[0112] in, It represents the second assessment value of Parkinson's patients at target treatment; It represents the minimum value of all physical sign data during the subsequent follow-up; It represents the minimum value of all physical sign data during the previous follow-up.

[0113] Then, the first and second evaluation values of Parkinson's patients in target treatment and the possibility of irreversible brain damage can be integrated to obtain the comprehensive evaluation value of Parkinson's patients in target treatment, and the comprehensive evaluation value of Parkinson's patients in target treatment can be normalized to limit the calculation results to range, thereby obtaining an assessment value of irreversible brain damage in Parkinson's patients under target treatment.

[0114] Preferably, in one embodiment of the present invention, the product of the first evaluation value and the second evaluation value of the Parkinson's patient in the target treatment and the possibility of irreversible brain damage can be used as the comprehensive evaluation value of the Parkinson's patient in the target treatment to achieve a combination of the three. In other embodiments of the present invention, the sum of the three can also be used as the comprehensive evaluation value of the Parkinson's patient in the target treatment to achieve a combination of the three.

[0115] As an example, in one embodiment of the present invention, the expression for the evaluation value of irreversible brain damage of Parkinson's patients under target treatment can be specifically, for example, as follows:

[0116]

[0117] in, It represents the assessment value of irreversible brain damage in Parkinson's patients at the target treatment; It represents the first assessment value of Parkinson's patients at the target treatment; It represents the second assessment value of Parkinson's patients at target treatment; Indicates the likelihood of irreversible brain damage in Parkinson's patients at the target of treatment; It represents the comprehensive assessment value of Parkinson's patients in target treatment; Represents a normalization function for normalization processing. In one embodiment of the present invention, the normalization processing can be specifically, for example, maximum and minimum value normalization processing. In other embodiments of the present invention, other normalization methods can be selected according to the specific range of numerical values, which will not be described in detail.

[0118] The same method mentioned above can be used to obtain the irreversible brain damage assessment value of Parkinson's disease patients in each repeated transcranial stimulation treatment, and then the irreversible brain damage assessment value of Parkinson's disease patients in all treatments can be uploaded to the database, thereby improving the effect of long-term follow-up of Parkinson's disease patients, so as to provide a data basis for relevant medical personnel to analyze the changing trend of irreversible brain damage in Parkinson's disease patients during long-term treatment. For example, by analyzing the changes in the irreversible brain damage assessment value of the patient in multiple treatments, the patient's treatment plan such as the frequency of repeated transcranial stimulation treatment can be better improved.

[0119] It should be noted that the order in which the embodiments of the present invention are described above is for illustrative purposes only and does not necessarily represent the superiority or inferiority of the embodiments. The processes depicted in the accompanying drawings do not necessarily require the specific order or sequential order shown to achieve the desired results. In certain embodiments, multitasking and parallel processing are also possible or may be advantageous.

[0120] The various embodiments in this specification are described in a progressive manner, and the same or similar parts between the various embodiments can be referred to each other. Each embodiment focuses on the differences from other embodiments.

Claims

1. A long-term follow-up method for repetitive transcranial stimulation therapy for Parkinson's disease patients, characterized in that: The method comprises: Obtain the physical sign data of Parkinson's patients at each follow-up examination before and after each repetitive transcranial stimulation treatment; Taking any treatment as the target treatment, the follow-up process before the target treatment as the preceding follow-up process, and the follow-up process after the target treatment as the subsequent follow-up process, and obtaining the trend value of the worsening condition of the Parkinson's disease patient during the target treatment based on the difference in the physical sign data of each follow-up examination between the preceding follow-up process and the subsequent follow-up process; any one of the preceding follow-up process or the subsequent follow-up process is used as a target follow-up process, and based on the changes in the physical sign data of each follow-up examination in the target follow-up process, a plurality of rebound sign data are screened from the physical sign data of all follow-up examinations in the target follow-up process; based on the changes in each rebound sign data in the target follow-up process and the number of all rebound sign data, an irreversible brain damage index of the Parkinson's patient in the target follow-up process is obtained; based on the irreversible brain damage index of the Parkinson's patient in the preceding follow-up process and the subsequent follow-up process, and the disease worsening trend value of the Parkinson's patient in the target treatment, a possibility of irreversible brain damage in the Parkinson's patient during the target treatment is obtained; Obtaining an assessment value of irreversible brain damage in the Parkinson's disease patient during the target treatment based on the likelihood of irreversible brain damage in the Parkinson's disease patient during the target treatment and the difference in distribution of the physical sign data in each follow-up examination between the previous follow-up process and the subsequent follow-up process, and uploading the assessment value of irreversible brain damage in the Parkinson's disease patient during all treatments to a database; The step of screening out a plurality of rebound physical sign data from the physical sign data of all follow-up examinations during the target follow-up process includes: Mapping the vital sign data of all follow-up examinations during the target follow-up process into a two-dimensional coordinate system to obtain a plurality of data points, wherein the horizontal axis of the two-dimensional coordinate system represents the sequence number of the follow-up examination and the vertical axis represents the vital sign data; Performing a curve fitting on all the data points to obtain a fitting curve, and using the follow-up examination corresponding to the minimum value data point on the fitting curve as a candidate follow-up examination in the target follow-up process; Obtaining a trend deviation of the physical sign data of each to-be-selected follow-up examination based on the physical sign data of each to-be-selected follow-up examination, the physical sign data of the first follow-up examination in the target follow-up process, the physical sign data of the last follow-up examination in the target follow-up process, the sequence number of each to-be-selected follow-up examination, and the number of all follow-up examinations in the target follow-up process; The average of the trend deviations of the physical sign data of all selected follow-up examinations is taken as the overall trend deviation; The physical sign data of the selected follow-up examination whose trend deviation is greater than the overall trend deviation is used as rebound physical sign data; The trend deviation of the physical sign data of each selected follow-up examination includes: The difference between the physical sign data of each candidate follow-up examination and the physical sign data of the first follow-up examination in the target follow-up process is used as the numerator, the difference between the physical sign data of the last follow-up examination in the target follow-up process and the physical sign data of the first follow-up examination in the target follow-up process is used as the denominator, and the ratio is used as the first proportional coefficient of each candidate follow-up examination; The serial number of each candidate follow-up examination is used as the numerator, the number of all follow-up examinations in the target follow-up process is used as the denominator, and the ratio is used as the second proportional coefficient of each candidate follow-up examination; Based on the calculation formula of trend deviation, the trend deviation of the physical sign data of each selected follow-up examination is obtained. The calculation formula of trend deviation is: in, Indicates the first The trend deviation of the physical sign data of the selected follow-up examinations; Indicates the The first proportionality coefficient of the selected follow-up examinations; Indicates the The second proportionality factor for the number of follow-up examinations to be selected; The irreversible brain damage indicators obtained for Parkinson's patients during the target follow-up process include: The cumulative value of the trend deviation of all the rebound sign data in the target follow-up process is used as the comprehensive trend deviation of the target follow-up process; The product value of the number of all the rebound sign data and the comprehensive trend deviation during the target follow-up process is used as an indicator of irreversible brain damage in Parkinson's patients during the target follow-up process.

2. A long-term follow-up method for repetitive transcranial stimulation therapy for Parkinson's disease patients according to claim 1, characterized in that: The values for obtaining the worsening trend of Parkinson's disease in patients with target treatment include: Normalizing the difference between the physical sign data of the last follow-up examination in the preceding follow-up process and the physical sign data of the first follow-up examination in the subsequent follow-up process to obtain the temporary impact of the target treatment; Obtaining the degree of sustained effect of the target treatment based on the difference in the overall level of the physical sign data of all follow-up examinations between the previous follow-up process and the subsequent follow-up process; The difference between the temporary impact level and the persistent impact level is used as the disease progression trend value of the Parkinson's disease patient under target treatment.

3. A long-term follow-up method for repetitive transcranial stimulation therapy for Parkinson's disease patients according to claim 2, characterized in that: The degree of sustained impact of achieving the desired treatment includes: The average value of the physical sign data of all follow-up examinations in the previous follow-up process is used as the first overall physical sign data of the previous follow-up process; The average value of the physical sign data of all follow-up examinations in the subsequent follow-up process is used as the second overall physical sign data of the subsequent follow-up process; The difference between the first overall vital sign data and the second overall vital sign data is normalized to obtain the degree of sustained impact of the target treatment.

4. The long-term follow-up method for repetitive transcranial stimulation therapy for Parkinson's disease patients according to claim 1, characterized in that: The potential for irreversible brain damage in Parkinson's patients receiving targeted treatment includes: The average value of the irreversible brain damage index of the Parkinson's patient during the preceding follow-up process and the subsequent follow-up process is used as the irreversible brain damage coefficient of the Parkinson's patient in the target treatment; The product value of the irreversible brain damage coefficient of the Parkinson's patient under target treatment and the disease worsening trend value is normalized to obtain the possibility of irreversible brain damage of the Parkinson's patient under target treatment.

5. The long-term follow-up method for repetitive transcranial stimulation therapy for Parkinson's disease patients according to claim 1, characterized in that: The evaluation values of irreversible brain damage in Parkinson's patients under target treatment include: In the preceding follow-up process, the number of all follow-up examinations after the follow-up examination corresponding to the maximum value of all the vital sign data is used as a first number of the preceding follow-up process; in the subsequent follow-up process, the number of all follow-up examinations before the follow-up examination corresponding to the maximum value of all the vital sign data is used as a second number of the subsequent follow-up process; and a sum of the first number and the second number is negatively correlated and mapped to obtain a first assessment value of the Parkinson's patient at the target treatment; Obtaining a second assessment value of the Parkinson's disease patient at target treatment based on a difference between a minimum value of all the physical sign data during a previous follow-up and a minimum value of all the physical sign data during a subsequent follow-up; Combining the first assessment value and the second assessment value of the Parkinson's patient under target treatment and the possibility of irreversible brain damage to obtain a comprehensive assessment value of the Parkinson's patient under target treatment; The comprehensive assessment values of Parkinson's patients under target treatment were normalized to obtain the assessment values of irreversible brain damage of Parkinson's patients under target treatment.

6. The long-term follow-up method for repetitive transcranial stimulation therapy for Parkinson's disease patients according to claim 5, characterized in that: Obtaining a second assessment value of the Parkinson's disease patient at target treatment includes: The minimum value of all the physical sign data in the subsequent follow-up process is used as the numerator, the minimum value of all the physical sign data in the previous follow-up process is used as the denominator, and the ratio is used as the second evaluation value of Parkinson's patients in target treatment.

7. The long-term follow-up method for repetitive transcranial stimulation therapy for Parkinson's disease patients according to claim 5, characterized in that: The comprehensive assessment of Parkinson's disease patients in target treatment includes: The product of the first assessment value, the second assessment value and the possibility of irreversible brain damage of the Parkinson's patient in the target treatment is used as the comprehensive assessment value of the Parkinson's patient in the target treatment.

Images